Introduction
The isolation of tissue-specific self-renewable stem cells from human embryonic or adult stem cells is one of the most promising applications for regenerative medicine. Ongoing research suggests that multipotent stem cells are a viable source of specialized cells for tissue repair. Undifferentiated stem cells are better suited when multiple cell types are lost to injury or disease. However, when a single lineage species is associated with an injury or disease, multipotent stem cells can be instructed to terminally differentiate into specific cell types. The terminal differentiation is induced by culturing the multipotent stem cells in media containing specific instructive molecules or by over-expressing lineage-specific gene(s). Further studies are needed to generate cellular phenotypes with stable expression in vitro and after grafting into diseased or injured tissue. Harnessing mechanisms governing tissue histogenesis that take place during early embryogenesis is a promising strategy for engineering specific cell types or tissues. Likewise, the same developmental pathways could also be induced in vitro using a set of instructive cues different from those normally involved during embryonic development. Within the framework of developing therapeutic products, this chapter will discuss the cellular and molecular control of neural stem cell derivation from adult and pluripotent stem cells and their differentiation into dopaminergic lineage.
Derivation and properties of neural stem cells
Neural stem cells (NSCs) are defined by their ability to self-renew and generate a large number of progeny able to differentiate into the principal central nervous system (CNS) cell types: neurons, astrocytes and oligodendrocytes. NSCs have the ability to maintain themselves in culture under genetic or epigenetic stimulation and to generate a large number of progeny. Contrary to the hematopoietic system where the hematopoietic stem cells are defined by a set of cell markers and thus can be purified by fluorescence-activated cell sorting (FACS), there are no specific cellular markers, necessary and sufficient to identify NSCs. The cell surface marker CD133 (prominin-1/2) epitope has been used to isolate the neurosphere-forming neural precursors from human fetal brain (Uchida et al., spinal cord motor neurons and midbrain dopamine neurons and to generate neural crest cells (Elkabetz et al., 2008) . Transplantation of the Force1+ neural precursors into the rat striatum led to graft overgrowth and formation of rosette in vivo. This overgrowth was observed even when Force1+ cells were sorted before transplantation suggesting that cell contamination is not the cause of the tumorigenicity. A recent study, however, demonstrated that neither CD133 nor CD15 are necessary markers to define a neural stem cell. Human NSCs positive or negative for either CD133 or CD15 have exhibited multipotency and the ability to differentiate into neurons, astrocytes and oligodendrocytes (Sun et al., 2009) . Of interest, the CD133 marker appears to be down regulated as the cells enter the S phase and during the G2 or M phases. This observation renders the neural stem cell identity even more elusive. In addition to cell surface markers, specific populations of NSCs may be isolated based on their responsiveness to mitogenic growth factors. The fundamental three properties necessary for cells to be defined as NSC are: 1) self-renewal ability and maintenance of longterm cultures through multiple passages under clonogenic conditions, 2) generation of a large number of progenies and 3) differentiation into the three principal neural lineages i.e. neurons, astrocytes and oligodendrocytes. Conti et al. isolated homogenous and clonogenic populations of NSCs from mouse and human ESC-derived rosettes (Conti et al., 2005) . The rosettes were mechanically transferred into serum free media in the presence of EGF and bFGF and propagated for up to 5 months. When exposed to appropriate differentiation factors, these NSCs expressed nestin, vimentin and the radial glial marker 3CB2 and differentiated into neurons, astrocytes and oligodendrocytes, (Sun et al., 2008) . After transplantation into adult mouse hippocampus and striatum, these NSCs engrafted and differentiated into neurons and astrocytes without forming tumors. Daadi et al. recently reported the isolation and perpetuation of a homogenous population of hNSCs, from hECSs based on their proliferative response to the exposure to EGF, bFGF and LIF (Daadi et al., 2008) . The cumulative cell number and population doubling analysis demonstrated the continuous and stable growth of the hNSCs. These hNSCs were clonogenic and expressed the neural precursor cell markers nestin, vimentin and the radial glial cell marker 3CB2. Under differentiation conditions, the hNSCs gave rise to neurons, astrocytes and oligodendrocytes, expressed transcripts for the neural-specific genes nestin, Notch1 and neural cell adhesion molecule (N-CAM), Sox2 and for the lineage specific markers β-tubulin class III, medium-size neurofilament (NF-M) and microtubule-associated protein 2 (MAP-2) for neurons, GFAP for astrocytes and myelin basic protein (MBP) for oligodendrocytes. Koch et al. recently reported the isolation, perpetuation and characterization of the rosettederived EGF+FGF2 responsive hNSCs (Koch et al., 2009 ). These neural precursors were isolated from rosettes dissected out of the culture plate and grown in suspension as spheres. In this study the self-renewable NSCs were maintained for up to 75 passages without apparent changes in proportions of the neural lineages and a pronounced differentiation toward neuronal lineage (40 to 70%). These NSCs developed an anterior hindbrain identity with predominant generation of GABAergic neurons. They retained the ability to convert to a ventral midbrain identity in response to sonic hedgehog (SHH) and FGF8 treatment with 31% of beta-tubulin+ neurons expressing tyrosine hydroxylase.
Another approach used to generate a homogeneous and specific NSC population at the clonal level is the genetic immortalization of neural precursors with propagating genes, such as v-myc, large T-antigen and telomerase reverse transcriptase (hTER) (Snyder et al., 1992; Whittemore and Synder, 1996; Lundberg et al., 1997; Roy et al., 2004) . Over expression of human telomerase reverse transcriptase (hTERT) was used to immortalize neural progenitors from the human fetal spinal cord. These cells have been shown to yield multiple cell lines with different lineage proportions including some restricted to a neuronal lineage both in vitro and in vivo. The cell line expressed markers consistent with a ventral spinal neuronal (interneurons and motor neurons) phenotype. The functional property of the neurons was demonstrated electrophysiologically by using calcium influx in response to depolarizing stimuli. The cells were passaged without evidence of senescence, karyotypic abnormality or loss of normal growth control. The cells did not form tumors or overgrow after transplantation into developing rat fetal telencephalon or spinal cord. Human NSC clones were genetically propagated using v-myc (Flax et al., 1998; Villa et al., 2009) . Transplantation of these hNSCs demonstrated their ability to migrate throughout the CNS and differentiate into multiple developmentally and regionally appropriate cell types. The gene product of v-myc was undetectable in grafted hNSCs 24-48 hours following transplantation, which suggests the lack of graft overgrowth in vivo. However, there is possibility of clonal variations in v-myc expression or re-activation of v-myc in vivo and tumor formation. Thus, regulated expression of immortalizing genes would be a safer approach for exploring therapeutic application of the immortalized cell lines (Hoshimaru et al., 1996) . The prospective isolation and perpetuation of homogenous populations of neural stem cells have also been carried out using reporter genes placed under the regulatory control of cellspecific promoters. Using human cells, this technique requires the transfection and FACS isolation of the cell population expressing the reporter gene, such as green fluorescent protein (GFP). Among the cell-specific gene promoters used to isolate neural stem cells are nestin, musashi, Sox1 and Sox2. Nestin is an intermediate filament expressed by neuroepithelial stem cells. The second intronic enhancer of nestin directs its transcription to neural stem and progenitor cells. This strategy was used to isolate homogenous nestin+ neural stem cells and to differentiate them into specific lineages (Keyoung et al., 2001) . Musashi1 is an RNA-binding protein expressed by neural progenitors of the fetal brain . Neural cells expressing the musashi1/hGFP co-expressed nestin in 96% of the progeny. The majority of cells (93%) are undergoing cell division as monitored by BrdU incorporation (Keyoung et al., 2001 ). Sox1 gene is one of the earliest genes that mark the neuroectoderm specification in the developing mouse embryo. It is expressed in neuroepithelial precursors but down-regulated during neuronal and glial differentiation. Using a Sox1-GFP knock-in line, purified populations of neural stem cells were isolated, perpetuated and differentiated into specialized neuronal populations. (Ying et al., 2003; Barraud et al., 2005; Chung et al., 2006) . Similarly, Zappone et al defined the regulatory element of Sox2 gene expression in both stem and progenitor cells (Zappone et al., 2000) . Using adenoviral vector expressing Sox2/EGFP Wang et al transduced and FACS purified Sox2 expressing neural stem cells from the developing human fetal brain (Wang et al.) . The Sox2+ neural precursors were self-renewable, multipotent and displayed higher telomerase enzymatic activity, in comparison to the Sox2-depleted population.
Therapeutic application in Parkinson's Disease
Parkinson's disease (PD) is a neurodegenerative disorder characterized by the loss of dopamine (DA) neurons in the substantia nigra pars compacta, resulting in decreased dopaminergic input to the striatum. Symptoms include tremors, rigidity, bradykinesia and instability. Existing therapies for PD are only palliative and treat the symptoms but do not address the underlying cause or prevent the progression of the disease. Levodopa (L-dopa), the gold standard pharmacological treatment to restore dopamine, is compromised over time by decreased efficacy and by increased side effects. Neurosurgical treatments, such as pallidotomy, thalamotomy and deep electrical stimulation are only considered after the failure of pharmacological treatment. A reliable long-term treatment to halt the progression of the disease and restore function remains elusive. Neural transplantation is a promising strategy for improving dopaminergic dysfunction in PD. Over 20 years of research using fetal mesencephalic tissue as a source of DA neurons has demonstrated the therapeutic potential of cell transplantation therapy in rodents and non-human primate animal models and in human patients (Mendez et al., 2008) . In many patients grafts have survived, formed synaptic connections and improved motor function (Olanow et al., 1997; Barker and Dunnett, 1999) . However, there are limitations associated with human fetal tissue transplantation, including high tissue variability, lack of scalability, ethical concerns and inability to obtain an epidemiologically meaningful quantity of tissue. Thus, the control of the identity, purity and potency of these cells becomes exceedingly difficult and jeopardizes both the safety of the patient and the efficacy of the therapy. With a reliance on fetal tissue as a source of neurons, cell replacement therapy cannot develop into a widely available treatment option for patients with neurodegenerative diseases. These critical issues render the search and development of alternative sources of cells a very worthwhile goal with societal importance and commercial application.
Differentiation of neural stem cells into dopaminergic neurons
Alternative sources of natural dopamine expressing cells explored have been the adrenal medulla cells (Schueler et al., 1993) , PC12 cells (Ono et al., 1997) , the glomus cells of the carotid bodies (Espejo et al., 1998) and the porcine fetal tissue (Deacon et al., 1997) . Most of these sources have been abandoned due to poor cell survival, inefficiency or health risks for the patient (Yurek and Sladek, 1990; Isacson and Breakefield, 1997) . The current most promising strategy in generating an unlimited supply of cells for neural transplantation is the generation of dopaminergic neurons from NSCs. Cellular differentiation may be defined as a multistep process driving a given cell from a precursor stage to functional competence. These steps often are manifested by changes in cellular morphology and by the appearance of new gene products. Each differentiation step is timely orchestrated and often depends on the interplay between the cell's intrinsic and extrinsic programs. Knowledge of both extrinsic differentiation signals and the molecular machinery underlying the intrinsic events is rapidly progressing. Extrinsic cues may regulate neuronal diversity by selectively rescuing a specific subpopulation of neuronal precursors committed to expressing a specific neurotransmitter phenotype or by instructing the neuronal precursors during a narrow developmental window to adopt a specific fate. The relative distribution of the in vivo environmental cues is thought to play a critical role in directing fate choices of stem cell neuronal progeny. For instance, in the peripheral nervous system (PNS), neural crest stem cells (NCSCs) derived from the E10.5 neural tube behave differently from the E14.5 sciatic nerve-derived NCSC. The latter became less sensitive to the autonomic instructive action of bone morphogenetic protein-2 (BMP-2) and consequently their potential is limited to a cholinergic fate. This time-dependant decrease in the BMP-2 sensitivity may have resulted from a combination of an in vivo selection and developmental change in the NCSCs mode to respond to BMP2. A promising stem cell source for DA neurons is embryonic stem (ES) cells. Early studies demonstrated that these cells have the potential to generate DA neurons (Kawasaki et al., 2000; Lee et al., 2000a) . In presence of serum, ES cells form clusters of floating cells or embryoid bodies (EBs) containing ectodermal, mesodermal and endodermal derivatives. When these EBs are treated with FGF2, FGF8 and Shh, 71% of the cells differentiated into neurons as identified with the neuronal marker class III β-tubulin and 33% of these neurons displayed characteristics of the midbrain DA neurons (Lee et al., 2000a) . A second group of investigators proceeded first to generate a homogenous neural lineage from the ES cells (Kawasaki et al., 2000) before inducing DA phenotype. This was achieved by co-culturing ES cells with the stromal cells PA6 that induced the pan-neural marker NCAM in 92% of the ES cells colonies. PA6-derived conditioned media was inefficient in inducing neural differentiation, but was not blocked by a 0.4 μm membrane barrier. Paradoxically, paraformaldehyde fixed PA6 cells retained the inductive activity. Under these culture conditions, 52% of differentiated cells expressed neuronal markers and 30% of these neurons assumed midbrain DA phenotype. These DA induced neurons appear to engraft after implantation and to improve behavioral deficits of 6-OHDA lesioned mice. Mesencephalic explant cultures studies (Baizabal and Covarrubias, 2009) showed that ES-derived neural precursors exhibit a limited developmental window to respond to the midbrain DA cues and that FGF8 +SHH treatment promotes commitment to DA lineage. There has been a concerted effort to isolate a stable, expandable stem cell from the midbrain, based on the hypothesis that the progeny will be destined or at least inducible to become the A9 class of the midbrain projecting DA neurons and differentiate exclusively into nigrostriatal-like DA neurons. Early studies have demonstrated that EGF responsive precursor cells do exist within the midbrain, however, these progeny did not consistently or robustly, differentiate into DA neurons neither in vitro (Mytilineou et al., 1992; Svendsen et al., 1995; Potter et al., 1999) nor after implantation into the rat striatum (Svendsen et al., 1996; Svendsen et al., 1997) . Interestingly, IL-1 induced TH expression in the midbrain-derived progenitors (Potter et al., 1999) . In addition, membrane-bound factors potentiated the TH induction and stimulated morphological maturation in these progenitors (Ptak et al., 1995; Ling et al., 1998) . The continuous generation of DA neurons from a long-term expandable midbrain-derived stem cell will require the development of processes for proliferation and maintenance of DA-specific precursors. Noteworthy, radial glia of the floor plate can give rise to the midbrain DA neurons in vivo (Bonilla et al., 2008) . In addition, ascorbic acid and lowered oxygen concentration appear to support survival and proliferation of DA neurons, respectively (Studer et al., 2000; Yan et al., 2001) . The effect of a low oxygen level (3±2%) was partially mimicked by erythropoietin (Epo). A different approach (Sawamoto et al., 2001) consisted of FACS sorting mesencephalic precursors according to their expression of GFP driven by nestin enhancer. Nestin is a neurofilament, expressed by neuroepithelial stem cells (Lendahl et al., 1990) . The nestin-GFP+ precursors were clonally analyzed and shown to have the ability to self renew and generate clusters of progeny able to differentiate into neurons, astrocytes and oligodendrocytes. Among this neuronal population TH+ neurons www.intechopen.com were identified with no particular treatment. Importantly, five weeks after implantation of the sorted GFP+ cells into the striatum of 6-OHDA hemiparkinsonian rats, the animals showed reduction in amphetamine induced rotation. Using this FACS approach, midbrain DA radial glial-like precursors were isolated at the embryonic age E10.5, based on the expression of Lmx1a and the floor plate marker Corin (Jonsson et al., 2009 ). This study and others highlight the therapeutic efficacy of the A9 DA progenitors in cell transplantation therapy for PD. As follow up to the 2 early studies described above (Kawasaki et al., 2000; Lee et al., 2000b) numerous reports have described techniques of generating dopaminergic neurons from hESCs (Schulz et al., 2004; Zeng et al., 2004; Park et al., 2005; Yan et al., 2005; Sonntag et al., 2007; Cho et al., 2008) . Some approaches require co-culturing with stromal cells, human astrocytes, meningeal, sertoli cells or others (Kawasaki et al., 2000; BuytaertHoefen et al., 2004; Perrier et al., 2004; Takagi et al., 2005; Roy et al., 2006; Yue et al., 2006; Chiba et al., 2008; Hayashi et al., 2008) . Studies have now begun to decipher the active components responsible for the DA phenotype induction. For instance, a recent study demonstrated that the DA-inductive signals of the stromal cell line was mimicked by the combination of a defined set of factors, including stromal cell-derived factor 1, pleiotrophin, insulin-like growth factor 2 and ephrin B1 (Vazin et al., 2009 ). The inducing factors in the other cell lines and signaling pathways involved in the DA specification remain to be determined.
Conclusions
Neural stem cells offer us a great tool for understanding the basic biology of cell fate choices and allow us to explore novel inducing factors and new developmental networks of gene cascades that may not necessarily occur under in vivo physiological conditions. A deeper and broader understanding of the molecular and cellular functioning in the development of specialized neural cells, strengthens our ability to efficiently produce stable, pure and viable sources of DA neurons. Ideally this knowledge will also enlighten the next step when cellular products are tested in vivo and pre-clinical efficacy is determined. Among challenging issues in product development for PD are the cell line stability, scalability, composition, efficiency in DA neurons generation, viability, cryo-preservation, recovery, identity, purity, potency and the in vivo fate of the implanted cell. Thus, given the complexity of neural system, long-term translational research will play an important and critical role in developing safe and efficacious cellular products for treating PD patients.
